

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report: June 27, 2014
(Date of earliest event reported)

BIORESTORATIVE THERAPIES, INC.
(Exact Name of Registrant as Specified in Charter)

Nevada	000-54402	91-1835664
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification Number)
555 Heritage Drive, Jupiter, Florida		33458
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code: (561) 904-6070

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On June 27, 2014, Joel San Antonio resigned as a director of BioRestorative Therapies, Inc. (the “Company”) due to other business commitments.

(d) On June 27, 2014, Paul Jude Tonna was elected a director of the Company. Mr. Tonna was appointed as a member of the Audit Committee, the Compensation Committee and the Nominating Committee of the Board. Concurrently with his election, Mr. Tonna was granted an option to purchase 300,000 shares of common stock of the Company at an exercise price of \$0.285 per share pursuant to the Company’s 2010 Equity Participation Plan (the “Plan”). The option vests to the extent of 100,000 shares on the date of grant, 100,000 shares on the first anniversary of the date of grant and 100,000 shares on the second anniversary of the date of grant and is exercisable for a period of ten years, subject to the provisions of the Plan.

On June 27, 2014, Joseph B. Swiader was elected a director of the Company. Mr. Swiader was appointed as a member of the Compensation Committee and the Nominating Committee of the Board. Concurrently with his election, Mr. Swiader was granted an option to purchase 300,000 shares of common stock of the Company at an exercise price of \$0.285 per share pursuant to the Plan. The option vests to the extent of 100,000 shares on the date of grant, 100,000 shares on the first anniversary of the date of grant and 100,000 shares on the second anniversary of the date of grant and is exercisable for a period of ten years, subject to the provisions of the Plan.

Item 8.01 Other Events.

On June 30, 2014, the Company issued a press release (the “Tonna Press Release”) announcing Mr. Tonna’s election. A copy of the Tonna Press Release is furnished as Exhibit 99.1 hereto.

On July 2, 2014, the Company issued a press release (the “Swiader Press Release”) announcing Mr. Swiader’s election. A copy of the Swiader Press Release is furnished as Exhibit 99.2 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release, dated June 30, 2014, issued by BioRestorative Therapies, Inc.

99.2 Press release, dated July 2, 2014, issued by BioRestorative Therapies, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIORESTORATIVE THERAPIES, INC.

Dated: July 3, 2014

By: /s/ Mark Weinreb
Mark Weinreb
Chief Executive Officer



BioRestorative Therapies Appoints The Honorable Paul Jude Tonna to its Board of Directors

JUPITER, Fla. (June 30, 2014) – BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB: BRTX), a life sciences company focused on adult stem cell-based cellular therapies for various personal medical applications, today announced the appointment of The Honorable Paul Jude Tonna to its Board of Directors. Mr. Tonna will serve on the Audit, Compensation and Nominating committees of the Board.

Mr. Tonna is a highly regarded community leader and an accomplished businessman with an extensive history of public service. From 1994 to 2005 he served as a Suffolk County Legislator, and from 2000 through 2002 was its Presiding Officer. He currently serves as Executive Director and a member of the Board of Advisors for The Energeia Partnership at Molloy College, a leadership academy based in Rockville Centre, New York, dedicated to identifying and addressing the serious, complex and multi-dimensional issues challenging the Long Island region.

Mr. Tonna is a former Adjunct Professor in Theology & Religious Studies at St. John's University. He served as Chairman of the Suffolk County Industrial Development Agency and currently serves as Public Trustee of the Stationary Engineer's Industry Stabilization Fund. Mr. Tonna is a board member of The Advanced Energy Research & Technology Center at Stony Brook University, The Long Island Index Advisory Board and Erase Racism's College of Advisors. He also serves as the Executive Director of the Suffolk County Village Officials Association and the United States Green Building Council-Long Island Chapter. Mr. Tonna is a founding director of Empire National Bank and Chairman and Commissioner of the South Huntington Water District.

"We are delighted to welcome Paul to the Board of Directors of BioRestorative Therapies," said Mark Weinreb, the Company's Chief Executive Officer. "He is a tireless advocate for so many social causes, including the environment, affordable housing, poverty and immigrant rights, and is the recipient of a host of awards and honors from a multitude of diverse groups. He is a remarkable man and we are excited to be able to draw from his wisdom as BioRestorative Therapies evolves."

Mr. Tonna holds an undergraduate degree in philosophy from New York University and a master's degree in theology from Immaculate Conception Seminary, and he conducted doctoral studies in systemic theology at Fordham University.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including:

- **brtxDISC™** (Disc Implanted Stem Cells) is an investigational non-surgical treatment for bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery. The treatment involves culturing a patient's own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure.
- **ThermoStem®** is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels.
- **brtx-C Cosmetic** is based on the development of a human cellular extract that has been demonstrated in *in vitro* skin studies to increase the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.

The Company also offers plant stem cell-based facial creams and beauty products under the **Stem Pearls®** brand at www.stempearls.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contacts:

LHA

Kim Sutton Golodetz

212-838-3777

kgolodetz@lhai.com

or

Bruce Voss

310-691-7100

bvoss@lhai.com

#



BioRestorative Therapies Appoints Joseph B. Swiader to its Board of Directors

JUPITER, Fla. (July 2, 2014) – BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB: BRTX), a life sciences company focused on adult stem cell-based cellular therapies for various personal medical applications, today announced the appointment of Joseph B. Swiader, age 54, to its Board of Directors. Mr. Swiader will chair the Nominating Committee and serve on the Compensation Committee of the Board.

Mr. Swiader has extensive experience in both the financial and biotechnology sectors. He is currently managing partner of Wet Earth Partners LLC, which he founded in 2002. Wet Earth Partners invests in a range of ventures that include biotechnology, medical technology and consumer products. Previously he was a partner at Feirstein Capital Management, where he oversaw investments in biotechnology, pharmaceutical, medical technology and healthcare services companies. Earlier Mr. Swiader was the Senior Global Healthcare Analyst at Scudder, Stevens & Clark (now part of Deutsche Asset & Wealth Management). Mr. Swiader was also a biotechnology and pharmaceutical analyst for the Dreyfus group of funds. He began his investment career in 1992 as a biotechnology analyst at JP Morgan Securities.

"As we advance our technologies through the regulatory pathway and position BioRestorative Therapies for growth, we have focused on deepening our corporate leadership and governance," said Mark Weinreb, Chief Executive Officer of BioRestorative Therapies. "Joe will provide a wealth of valuable experience in both finance and biotechnology, and we are very pleased he has agreed to join our Board of Directors."

Mr. Swiader received a Bachelor of Science degree in finance from Babson College in 1992.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including:

- **brtxDISC™ (Disc Implanted Stem Cells)** is an investigational non-surgical treatment for bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery. The treatment involves culturing a patient's own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure.
 - **ThermoStem®** is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels.
 - **brtx-C Cosmetic** is based on the development of a human cellular extract that has been demonstrated in *in vitro* skin studies to increase the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
-

The Company also offers plant stem cell-based facial creams and beauty products under the **Stem Pearls®** brand at www.stempearls.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contacts:

LHA

Kim Sutton Golodetz

212-838-3777

kgolodetz@lhai.com

or

Bruce Voss

310-691-7100

bvoss@lhai.com

#